← Back to Search

Pharmacist Alerts for Blood Clot Management

N/A
Recruiting
Led By Geoffrey Barnes, MD
Research Sponsored by University of Michigan
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Timeline
Screening 3 weeks
Treatment Varies
Follow Up month 0, up to 18 months
Awards & highlights
No Placebo-Only Group

Summary

This trial will test whether getting alerts about high-risk prescriptions from pharmacists, instead of doctors, will lead to more changes in prescriptions.

Who is the study for?
This trial is for Michigan Medicine providers with prescribing privileges in ambulatory care settings who prescribe direct oral anticoagulants (DOAC) to patients aged 18 and older. Providers working in inpatient settings or those part of the study team cannot participate.
What is being tested?
The study tests if alerts about prescriptions sent to pharmacists lead to more prescription changes than alerts sent to prescribers. It also examines if having a pharmacist referral option increases prescription changes when initial-prescribing errors occur.
What are the potential side effects?
Since this trial focuses on communication processes rather than medical treatments, there are no direct side effects from interventions being studied. However, changes in anticoagulant use could indirectly affect patient outcomes.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~month 0, up to 18 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and month 0, up to 18 months for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
The number (proportion) of notifications (in the existing-prescription notification conditions) that are addressed within 7 days.
Secondary study objectives
Change in effect size for the existing-prescription notification over time
Change in effect size for the initial alert over time
The number (proportion) of alerts (in the newly prescribed DOAC alert conditions) that are addressed within 7 days.

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

4Treatment groups
Experimental Treatment
Group I: New-prescription Alert/ Existing-prescription notification to pharmacistExperimental Treatment2 Interventions
Group II: New-prescription Alert w/ referral option/ Existing-prescription notification to prescriberExperimental Treatment2 Interventions
Group III: New-prescription Alert w/ referral option/ Existing-prescription notification to pharmacistExperimental Treatment2 Interventions
Group IV: New-prescription Alert / Existing-prescription notification to prescriberExperimental Treatment2 Interventions

Find a Location

Who is running the clinical trial?

Agency for Healthcare Research and Quality (AHRQ)FED
406 Previous Clinical Trials
6,752,205 Total Patients Enrolled
3 Trials studying Deep Vein Thrombosis
1,078 Patients Enrolled for Deep Vein Thrombosis
University of MichiganLead Sponsor
1,855 Previous Clinical Trials
6,430,061 Total Patients Enrolled
2 Trials studying Deep Vein Thrombosis
133 Patients Enrolled for Deep Vein Thrombosis
Geoffrey Barnes, MDPrincipal InvestigatorUniversity of Michigan

Media Library

New-prescription Alert Clinical Trial Eligibility Overview. Trial Name: NCT05351749 — N/A
Deep Vein Thrombosis Research Study Groups: New-prescription Alert / Existing-prescription notification to prescriber, New-prescription Alert/ Existing-prescription notification to pharmacist, New-prescription Alert w/ referral option/ Existing-prescription notification to pharmacist, New-prescription Alert w/ referral option/ Existing-prescription notification to prescriber
Deep Vein Thrombosis Clinical Trial 2023: New-prescription Alert Highlights & Side Effects. Trial Name: NCT05351749 — N/A
New-prescription Alert 2023 Treatment Timeline for Medical Study. Trial Name: NCT05351749 — N/A
~1538 spots leftby Nov 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top